# Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH)

> **NCT00922506** · PHASE4 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 83 (actual)

## Conditions studied

- Overactive Bladder
- Benign Prostatic Hyperplasia

## Interventions

- **DRUG:** doxazosin plus tolterodine SR

## Key facts

- **NCT ID:** NCT00922506
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2014-05
- **Final completion:** 2014-06
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2019-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00922506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00922506, "Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00922506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*